Literature DB >> 18190867

Novel approaches to the treatment of cachexia.

Josep M Argilés1, Francisco J López-Soriano, Sílvia Busquets.   

Abstract

Cachexia is a complex syndrome. The main components of this pathological state are anorexia and metabolic abnormalities, such as glucose intolerance, fat depletion and muscle protein catabolism among others. The aim of the present article is to review the recent therapeutic approaches that have been designed to fight and counteract muscle wasting in different pathological states such as cancer, AIDS and chronic heart failure.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18190867     DOI： 10.1016/j.drudis.2007.10.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  19 in total

Review 1.  Symptom management in geriatric oncology: practical treatment considerations and current challenges.

Authors:  Katharine L Barford; James T D'Olimpio
Journal:  Curr Treat Options Oncol       Date:  2008-07-25

2.  THE RENIN-ANGIOTENSIN SYSTEM AND THE BIOLOGY OF SKELETAL MUSCLE: MECHANISMS OF MUSCLE WASTING IN CHRONIC DISEASE STATES.

Authors:  Patrice Delafontaine; Tadashi Yoshida
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

3.  Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia.

Authors:  Michelle L Asp; Min Tian; Kara L Kliewer; Martha A Belury
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

4.  Mechanisms of Cachexia in Chronic Disease States.

Authors:  Tadashi Yoshida; Patrice Delafontaine
Journal:  Am J Med Sci       Date:  2015-10       Impact factor: 2.378

Review 5.  Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia.

Authors:  Tadashi Yoshida; A Michael Tabony; Sarah Galvez; William E Mitch; Yusuke Higashi; Sergiy Sukhanov; Patrice Delafontaine
Journal:  Int J Biochem Cell Biol       Date:  2013-06-13       Impact factor: 5.085

Review 6.  Cancer cachexia: medical management.

Authors:  Giovanni Mantovani; Clelia Madeddu
Journal:  Support Care Cancer       Date:  2009-08-18       Impact factor: 3.603

7.  Selecting for predisposition to cancer cachexia.

Authors:  Ioannis Gioulbasanis; Panagiotis J Vlachostergios; Christos N Papandreou
Journal:  EMBO Mol Med       Date:  2012-04-11       Impact factor: 12.137

8.  Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance.

Authors:  Sílvia Busquets; Míriam Toledo; Marcel Orpí; David Massa; Maria Porta; Eva Capdevila; Núria Padilla; Valentina Frailis; Francisco J López-Soriano; H Q Han; Josep M Argilés
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-11-08       Impact factor: 12.910

9.  The translation inhibitor pateamine A prevents cachexia-induced muscle wasting in mice.

Authors:  Sergio Di Marco; Anne Cammas; Xian Jin Lian; Erzsebet Nagy Kovacs; Jennifer F Ma; Derek T Hall; Rachid Mazroui; John Richardson; Jerry Pelletier; Imed Eddine Gallouzi
Journal:  Nat Commun       Date:  2012-06-12       Impact factor: 14.919

10.  Theophylline is able to partially revert cachexia in tumour-bearing rats.

Authors:  Mireia Olivan; Jochen Springer; Sílvia Busquets; Anika Tschirner; Maite Figueras; Miriam Toledo; Cibely Fontes-Oliveira; Maria Inés Genovese; Paula Ventura da Silva; Angelica Sette; Francisco J López-Soriano; Stefan Anker; Josep M Argilés
Journal:  Nutr Metab (Lond)       Date:  2012-08-21       Impact factor: 4.169
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.